Aliases & Classifications for Papilloma

MalaCards integrated aliases for Papilloma:

Name: Papilloma 12 55 15 73
Papillomatosis 12 55 73

Classifications:



External Ids:

Disease Ontology 12 DOID:2615
MeSH 44 D010212
NCIt 50 C3713 C7440

Summaries for Papilloma

Disease Ontology : 12 A cell type benign neoplam that is composed_of epithelial tissue on papillae of vascularized connective tissue.

MalaCards based summary : Papilloma, also known as papillomatosis, is related to inverted papilloma and bladder transitional cell papilloma. An important gene associated with Papilloma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Developmental Biology and Cellular Senescence (REACTOME). The drugs Cervarix and Cidofovir have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and cervix, and related phenotypes are growth/size/body region and cellular

Wikipedia : 76 A papilloma (plural papillomas or papillomata) (papillo- + -oma) is a benign epithelial tumor growing... more...

Related Diseases for Papilloma

Diseases related to Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 416)
# Related Disease Score Top Affiliating Genes
1 inverted papilloma 34.5 CDKN2A KRT13 KRT20 TP53
2 bladder transitional cell papilloma 34.5 CDKN1A TP53
3 frontal sinus inverted papilloma 34.3 KRT13 KRT5
4 inverted transitional papilloma 34.1 CDKN2A KRT5
5 anogenital venereal wart 33.3 CDKN2A TP53 UBE3A
6 urinary tract papillary transitional cell benign neoplasm 33.0 KRT20 TP53
7 li-fraumeni syndrome 32.4 CDKN1A CDKN2A PTEN TP53
8 oral cancer 31.2 CDKN2A KRT13 TP53
9 suppressor of tumorigenicity 3 31.1 CDKN1A CDKN2A RB1 TP53 UBE3A
10 cervical cancer 31.1 CDKN1A CDKN2A PTEN RB1 TP53 UBE3A
11 retinoblastoma 30.9 CDKN1A CDKN2A RB1 TP53
12 adenocarcinoma 30.8 CDKN2A PTEN RB1 TP53
13 cervical squamous cell carcinoma 30.8 CDKN2A KRT8 TP53
14 bowenoid papulosis 30.7 CDKN2A FLG
15 vulvar intraepithelial neoplasia 30.7 KRT5 TP53
16 tongue cancer 30.7 CDKN1A CDKN2A KRT13 TP53
17 transitional cell carcinoma 30.6 CDKN2A KRT20 KRT8 PTEN TP53
18 lymphoepithelioma-like carcinoma 30.6 KRT20 KRT5 KRT8
19 schneiderian carcinoma 30.5 CDKN2A KRT5 TP53
20 bladder squamous cell carcinoma 30.5 CDKN2A PTEN TP53
21 endometrial adenocarcinoma 30.5 CDKN2A PTEN TP53
22 adenosquamous carcinoma 30.4 KRT5 KRT8 TP53
23 keratoacanthoma 30.3 CDKN1A FLG KRT10 TP53
24 cervical adenocarcinoma 30.3 CDKN1A CDKN2A KRT20 TP53
25 ductal carcinoma in situ 30.3 KRT14 KRT5 KRT8 TP53
26 bladder cancer 30.2 CDKN1A CDKN2A KRT20 RB1 TP53
27 squamous cell carcinoma, head and neck 30.2 CDKN1B CDKN2A PTEN RB1 TP53
28 epidermodysplasia verruciformis 30.2 CDKN2A KRT10 KRT14
29 actinic keratosis 30.2 CDKN2A FLG KRT20 TP53
30 basaloid squamous cell carcinoma 30.1 CDKN2A KRT13 KRT14 KRT8 TP53
31 squamous cell carcinoma 30.0 CDKN1B CDKN2A IVL PTEN RB1 TP53
32 in situ carcinoma 29.8 CDKN2A KRT14 KRT5 TP53
33 small cell cancer of the lung 29.7 CDKN2A KRT20 PTEN RB1 TP53
34 ichthyosis vulgaris 29.4 FLG KRT10 KRT14
35 adenoid cystic carcinoma 29.3 KRT14 KRT20 PTEN TP53
36 keratosis 29.3 FLG IVL KRT10
37 lichen planus 29.3 FLG IVL KRT10 KRT13 TP53
38 large cell acanthoma 29.2 KRT10 KRT14 KRT5
39 glioblastoma 29.1 CDKN1A CDKN1B CDKN2A CDKN2B PTEN RB1
40 esophageal cancer 29.0 CDKN1A CDKN1B CDKN2A CDKN2B FSCN1 PTEN
41 basal cell carcinoma 26.9 CDKN1A IVL KRT10 KRT14 KRT20 KRT8
42 papilloma of choroid plexus 12.5
43 squamous cell papilloma 12.3
44 intraductal papilloma 12.2
45 skin papilloma 12.0
46 atypical choroid plexus papilloma 12.0
47 transitional papilloma 12.0
48 breast duct papilloma 12.0
49 ureter inverted papilloma 12.0
50 maxillary sinus inverted papilloma 11.9

Graphical network of the top 20 diseases related to Papilloma:



Diseases related to Papilloma

Symptoms & Phenotypes for Papilloma

MGI Mouse Phenotypes related to Papilloma:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.29 CDKN1B FSCN1 AMOT CDKN2A CDKN1A TP53
2 cellular MP:0005384 10.28 CDKN2A CDKN1A CDKN2B FSCN1 CDKN1B AMOT
3 embryo MP:0005380 10.21 CDKN1B FSCN1 AMOT CDKN2A CDKN1A TP53
4 mortality/aging MP:0010768 10.21 CDKN2B CDKN1B FSCN1 AMOT CDKN2A CDKN1A
5 digestive/alimentary MP:0005381 10.18 CDKN1B CDKN2A CDKN1A TP53 PTEN KRT14
6 endocrine/exocrine gland MP:0005379 10.15 CDKN2A CDKN1A CDKN2B CDKN1B PTEN KRT14
7 integument MP:0010771 10.13 CDKN2B CDKN1B KRT14 CDKN2A CDKN1A TP53
8 liver/biliary system MP:0005370 9.95 CDKN2A CDKN1A CDKN1B KRT8 PTEN RB1
9 hearing/vestibular/ear MP:0005377 9.93 CDKN1A CDKN1B KRT8 KRT14 RB1 TP53
10 neoplasm MP:0002006 9.92 CDKN2B CDKN1B CDKN2A CDKN1A TP53 PTEN
11 no phenotypic analysis MP:0003012 9.86 CDKN2A CDKN1A CDKN2B CDKN1B RB1 KRT5
12 reproductive system MP:0005389 9.65 CDKN2A CDKN1A CDKN2B CDKN1B KRT8 TP53
13 pigmentation MP:0001186 9.63 CDKN1B CDKN2A TP53 PTEN KRT14 RB1
14 respiratory system MP:0005388 9.17 CDKN2A CDKN1A CDKN1B RB1 PTEN KRT14

Drugs & Therapeutics for Papilloma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Cervarix 18 49 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009

Drugs for Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 257)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cidofovir Approved Phase 4,Phase 2,Phase 1 113852-37-2 60613
2
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
3
Imiquimod Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99011-02-6 57469
4 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Anti-Infective Agents, Local Phase 4
11 Chlorhexidine gluconate Phase 4
12 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Disinfectants Phase 4
14 Hypoglycemic Agents Phase 4
15 Polyhexamethylene biguanide Phase 4
16 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
17 MF59 oil emulsion Phase 4
18 Adjuvants, Immunologic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Interferon Inducers Phase 4,Phase 2,Phase 3,Phase 1
20 interferons Phase 4,Phase 2,Phase 3,Phase 1
21
Azithromycin Approved Phase 3,Not Applicable 83905-01-5 55185 447043
22
Cetuximab Approved Phase 3,Phase 1,Phase 2,Not Applicable 205923-56-4 56842117 2333
23
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
24
Penicillin G Approved, Vet_approved Phase 3 61-33-6 5904
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
26
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
27
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
28
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
29
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
30
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
31
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
32
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
33
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
34
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
35
Zinc Approved, Investigational Phase 3,Not Applicable 7440-66-6 23994
36
Zinc sulfate Approved, Investigational Phase 3,Not Applicable 7733-02-0
37 tannic acid Approved, Nutraceutical Phase 3
38 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
39
Lapatinib Approved March 2007, Investigational Phase 3,Phase 2 231277-92-2, 388082-78-8 208908 9941095
40 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
41 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
42 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Not Applicable
43 Pharmaceutical Solutions Phase 3,Phase 2,Not Applicable
44 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
45 Penicillin G Benzathine Phase 3
46 Penicillin G Procaine Phase 3
47 Adjuvants, Anesthesia Phase 3
48 Analgesics Phase 3,Phase 2,Phase 1
49 Analgesics, Opioid Phase 3
50 Anesthetics Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 392)
# Name Status NCT ID Phase Drugs
1 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
2 Use of Cidofovir for Recurrent Respiratory Papillomatosis Completed NCT00205374 Phase 4 Cidofovir;Placebo
3 A Health Belief Model Based Intervention to Increase Human Papilloma Virus (HPV) Vaccination Among College Men Completed NCT01431079 Phase 4
4 Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine Completed NCT01740245 Phase 4
5 Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls Completed NCT00956553 Phase 4
6 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
7 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
8 MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine Completed NCT02225327 Phase 4
9 Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
10 Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study) Recruiting NCT03391921 Phase 4
11 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
12 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Active, not recruiting NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
13 HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) Active, not recruiting NCT02087384 Phase 4 Placebo
14 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Not yet recruiting NCT03350698 Phase 4
15 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Not yet recruiting NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
16 Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Terminated NCT00747461 Phase 4
17 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
18 Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City Unknown status NCT02382900 Phase 3
19 4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children Unknown status NCT01995721 Phase 3
20 Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
21 Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine Completed NCT00316706 Phase 3
22 Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18. Completed NCT00196924 Phase 3
23 Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18 Completed NCT00169494 Phase 3
24 Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) Completed NCT00380367 Phase 3
25 Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 Completed NCT00122681 Phase 3
26 Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18 Completed NCT00196937 Phase 3
27 Efficacy and Tolerability Study of V501 in Japanese Males (V501-122) Completed NCT01862874 Phase 3
28 Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women Completed NCT00337818 Phase 3
29 A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men Completed NCT02114385 Phase 3
30 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
31 Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years Completed NCT00345878 Phase 3
32 Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women Completed NCT00344032 Phase 3
33 Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age Completed NCT00423046 Phase 3
34 Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) Completed NCT00157950 Phase 3
35 Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects Completed NCT00578227 Phase 3
36 A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years Completed NCT00485732 Phase 3
37 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
38 Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls Completed NCT01381575 Phase 3
39 Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age Completed NCT00552279 Phase 3
40 ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
41 A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). Completed NCT01254643 Phase 3
42 Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea Completed NCT01955252 Phase 3 Azithromycin
43 Glizigen-Viudid-External Anogenital Warts in Children and Adolescents Completed NCT01111344 Phase 3
44 Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age Completed NCT00492544 Phase 3
45 Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years Completed NCT00456807 Phase 3
46 A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls Completed NCT02562508 Phase 3
47 A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix Completed NCT00264732 Phase 2, Phase 3 Amolimogene;Amolimogene
48 Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00735462 Phase 3 2.5% imiquimod cream;3.75% imiquimod cream;Placebo cream
49 Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia Completed NCT01164722 Phase 3
50 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo

Search NIH Clinical Center for Papilloma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Papilloma

Anatomical Context for Papilloma

MalaCards organs/tissues related to Papilloma:

41
Testes, Skin, Cervix, Lung, Kidney, Breast, Brain

Publications for Papilloma

Articles related to Papilloma:

(show top 50) (show all 1945)
# Title Authors Year
1
Clinical features of nasal and sinonasal inverted papilloma associated with malignancy. ( 29548524 )
2018
2
Malignant Transformation of a Canine Papillomavirus Type 1-Induced Persistent Oral Papilloma in a 3-Year-Old Dog. ( 29865982 )
2018
3
Degenerated Keratinized Tumor Cells in Oropharyngeal Human Papilloma Virus-Associated Squamous Cell Carcinoma: A Pitfall in p16 Immunostaining of Fine-Needle Aspiration Specimens. ( 29966127 )
2018
4
Human Papilloma Virus and Autophagy. ( 29914057 )
2018
5
Genotype patterns and prevalence of human papilloma virus in non-vaccinated women in Zunyi, China. ( 29915851 )
2018
6
Human Papilloma Virus 16/18: Fabricator of Trouble in Oral Squamous Cell Carcinoma. ( 29432879 )
2018
7
Prognostic Significance of Human Papilloma Virus and p16 Expression in Patients with Vulvar Squamous Cell Carcinoma who Received Radiotherapy. ( 29449057 )
2018
8
Assessing the performance of a Loop Mediated Isothermal Amplification (LAMP) assay for the detection and subtyping of high-risk suptypes of Human Papilloma Virus (HPV) for Oropharyngeal Squamous Cell Carcinoma (OPSCC) without DNA purification. ( 29422018 )
2018
9
Human papilloma virus-specific T cells can be generated from naA^ve T cells for use as an immunotherapeutic strategy for immunocompromised patients. ( 29331266 )
2018
10
Improving human papilloma virus vaccination rates throughout military treatment facilities. ( 29433899 )
2018
11
Intraductal papilloma arising from the accessory parotid gland: A case report and literature review. ( 29768362 )
2018
12
Laryngeal squamous cell papilloma is highly associated with human papillomavirus. ( 29447361 )
2018
13
Detection of urinary Chlamydia trachomatis, Mycoplasma genitalium and human papilloma virus in the first trimester of pregnancy by PCR method. ( 29866110 )
2018
14
DNA fragmentation index and human papilloma virus in males with previous assisted reproductive technology failures. ( 29975635 )
2018
15
Radiographic Imaging Does Not Reliably Predict Macroscopic Extranodal Extension in Human Papilloma Virus-Associated Oropharyngeal Cancer. ( 29969771 )
2018
16
Detection of Epstein-Barr and Human Papilloma Viruses in the Middle Ear Squamous Cell Carcinoma. ( 29456946 )
2018
17
Association between Human Papilloma Virus (HPV) vaccination and risk of Multiple Sclerosis: A systematic review. ( 29333935 )
2018
18
Amyotrophic Lateral Sclerosis after Receiving the Human Papilloma Virus Vaccine: A Case Report of a 15-year-old Girl. ( 29434138 )
2018
19
Mammographic and ultrasound findings in poroid hidradenoma of the breast mimicking intraductal papilloma and papillary carcinoma: A case report. ( 29924021 )
2018
20
Extensive Mucocutaneous Papillomas in a Case of Focal Dermal Hypoplasia. ( 29854650 )
2018
21
Better surgical outcome by image-guided navigation system in endoscopic removal of sinonasal inverted papilloma. ( 29678350 )
2018
22
A unique presentation of an adolescent with disseminated atypical choroid plexus papilloma. ( 29770898 )
2018
23
Genetic mutation analysis of the malignant transformation of sinonasal inverted papilloma by targeted amplicon sequencing. ( 29779136 )
2018
24
Knowledge And Perception Of Female Nursing Students About Human Papilloma Virus (Hpv), Cervical Cancer And Attitudes Towards Hpv Vaccination. ( 29979917 )
2018
25
Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review). ( 29393378 )
2018
26
Oncocytic Schneiderian papilloma-associated adenocarcinoma and KRAS mutation: A case report. ( 29879069 )
2018
27
Human Papilloma Virus and the Nurse's Role in Education and Prevention. ( 29905584 )
2018
28
Human Papilloma Virus (HPV) self-sampling: do women accept it? ( 29385850 )
2018
29
Management of Inverted Papilloma During Holmium Laser Enucleation of the Prostate. ( 29545053 )
2018
30
Poor Knowledge of Human Papilloma Virus and Vaccination Among Respondents from Three Nigerian States. ( 29922993 )
2018
31
A Tale of Two Tumors: a Case of Concomitant Esophageal Squamous Papilloma and Granular Cell Tumor. ( 29453760 )
2018
32
Optical coherence tomography and confocal laser scanning microscopy as non-invasive tools in the diagnosis of sinonasal inverted papilloma: a pilot study. ( 29737509 )
2018
33
Raman Spectroscopy for Inverted Papilloma: A Proof-of-Concept Study. ( 29763337 )
2018
34
Knowledge, Decision-Making and Acceptance of Human Papilloma Virus Vaccination among Parents of Primary School Students in Kota Bharu, Kelantan, Malaysia ( 29936724 )
2018
35
Endoscopic mucosal resection of rectal squamous cell papilloma. ( 29351698 )
2018
36
Atypical Presentation of Squamous Papilloma. ( 29342034 )
2018
37
Oncogenic Viruses and Breast Cancer: Mouse Mammary Tumor Virus (MMTV), Bovine Leukemia Virus (BLV), Human Papilloma Virus (HPV), and Epstein-Barr Virus (EBV). ( 29404275 )
2018
38
A unique case of a huge mixed squamous cell and glandular papilloma of non-endobronchial origin with a peripheral growth. ( 29977775 )
2018
39
Use of intraoperative negative margins reduces inverted papilloma recurrence. ( 29336292 )
2018
40
Human papillomavirus: An unlikely etiologic factor in sinonasal inverted papilloma. ( 29668071 )
2018
41
Analysis of miRNA expression profiling identifies miR-214-3p as a novel biomarker in sinonasal inverted papilloma. ( 29952653 )
2018
42
Benign inverted papilloma at bladder neck causing acute urinary retention. ( 29942474 )
2018
43
Advancements in electrochemical DNA sensor for detection of human papilloma virus? A review. ( 29981317 )
2018
44
Management of intraductal papilloma without atypia of the breast diagnosed on core biopsy: Size and sampling matter. ( 29687535 )
2018
45
Benign Intraductal Papilloma without Atypia on Core Needle Biopsy Has a Low Rate of Upgrading to Malignancy after Excision. ( 29628987 )
2018
46
Efficacy and safety of photodynamic therapy for cervical intraepithelial neoplasia and human papilloma virus infection: A systematic review and meta-analysis of randomized clinical trials. ( 29794788 )
2018
47
Human Papilloma Virus Vaccination Among Adolescents in a Community Clinic Before and After Intervention. ( 29368102 )
2018
48
Survivin and cortactin expression in sinonasal schneiderian (inverted) papilloma and associated carcinoma. ( 29644904 )
2018
49
Endoscopic management of maxillary sinus inverted papilloma attachment sites to minimize disease recurrence. ( 29618385 )
2018
50
Sinonasal papilloma: what influences the decision to request a magnetic resonance imaging scan? ( 29909780 )
2018

Variations for Papilloma

Expression for Papilloma

Search GEO for disease gene expression data for Papilloma.

Pathways for Papilloma

Pathways related to Papilloma according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.51 FLG IVL KRT10 KRT13 KRT14 KRT20
2
Show member pathways
13.14 CDKN1A CDKN1B CDKN2A CDKN2B RB1 TP53
3
Show member pathways
12.98 CDKN1A CDKN1B PTEN RB1 TP53 UBE3A
4
Show member pathways
12.88 CDKN1A CDKN1B CDKN2A PTEN RB1 TP53
5 12.83 CDKN1A CDKN1B CDKN2A CDKN2B PTEN RB1
6
Show member pathways
12.75 CDKN1A CDKN1B CDKN2A CDKN2B PTEN RB1
7
Show member pathways
12.73 CDKN1A CDKN1B CDKN2A CDKN2B PTEN RB1
8
Show member pathways
12.7 CDKN1A CDKN1B RB1 TP53 UBE2L3
9
Show member pathways
12.58 CDKN1A CDKN1B PTEN RB1 TP53
10
Show member pathways
12.57 CDKN1A CDKN1B CDKN2A CDKN2B RB1 TP53
11 12.52 CDKN1A CDKN1B CDKN2A RB1 TP53
12 12.51 CDKN1A CDKN1B CDKN2A FSCN1 PTEN TP53
13 12.47 AMOT FSCN1 KRT10 KRT13 KRT20 KRT5
14 12.44 CDKN1A CDKN2A CDKN2B RB1 TP53
15
Show member pathways
12.35 CDKN1A CDKN1B RB1 TP53
16
Show member pathways
12.34 CDKN1A CDKN1B CDKN2A PTEN RB1 TP53
17 12.31 CDKN1A CDKN1B CDKN2A CDKN2B RB1 TP53
18 12.29 CDKN1A CDKN1B RB1 TP53
19
Show member pathways
12.28 CDKN1A CDKN1B CDKN2A CDKN2B RB1 TP53
20
Show member pathways
12.26 CDKN1A PTEN RB1 TP53
21
Show member pathways
12.23 CDKN1A CDKN1B CDKN2A CDKN2B RB1
22 12.15 CDKN1A CDKN1B PTEN TP53
23
Show member pathways
12.1 CDKN1A CDKN1B CDKN2B PTEN
24 12.1 CDKN1A CDKN1B CDKN2A CDKN2B RB1 TP53
25 12.09 CDKN1A CDKN2A CDKN2B PTEN RB1 TP53
26 12.08 CDKN1A PTEN RB1 TP53
27 12.06 CDKN1A CDKN2A RB1 TP53 UBE3A
28
Show member pathways
12.05 CDKN1A CDKN1B PTEN TP53
29
Show member pathways
12.01 FLG IVL KRT10 KRT13 KRT14 KRT20
30
Show member pathways
11.97 KRT13 KRT14 KRT5 KRT8
31 11.97 CDKN1A CDKN1B CDKN2A PTEN TP53
32
Show member pathways
11.9 CDKN1A CDKN1B TP53
33 11.89 CDKN1A PTEN RB1 UBE3A
34 11.89 CDKN1A CDKN1B CDKN2A PTEN RB1 TP53
35 11.86 CDKN1A CDKN1B RB1 TP53
36 11.82 CDKN1A KRT14 KRT5 TP53
37 11.82 CDKN1A CDKN1B CDKN2A PTEN RB1 TP53
38 11.76 CDKN1A CDKN2A RB1 TP53
39 11.75 CDKN1A CDKN1B KRT8
40 11.74 CDKN1A CDKN1B RB1
41 11.74 CDKN1A CDKN2A TP53
42 11.65 CDKN1A CDKN1B CDKN2B
43 11.6 CDKN1A CDKN1B RB1
44 11.6 CDKN1A CDKN1B CDKN2B PTEN RB1 TP53
45 11.56 CDKN1A CDKN2A RB1 TP53
46 11.55 CDKN1A CDKN1B TP53
47 11.53 CDKN1A CDKN1B RB1
48 11.32 CDKN2A CDKN2B TP53
49 11.14 CDKN2A RB1 TP53
50
Show member pathways
11.14 CDKN1A CDKN2A TP53

GO Terms for Papilloma

Cellular components related to Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 PML body GO:0016605 9.58 PTEN RB1 TP53
2 cytosol GO:0005829 9.58 AMOT CDKN1A CDKN1B CDKN2A CDKN2B FLG
3 keratin filament GO:0045095 9.56 KRT13 KRT14 KRT5 KRT8
4 cornified envelope GO:0001533 9.54 FLG IVL KRT10
5 intermediate filament GO:0005882 9.5 FLG KRT10 KRT13 KRT14 KRT20 KRT5
6 cytoplasm GO:0005737 10.2 CDKN1A CDKN1B CDKN2A CDKN2B FSCN1 IVL
7 nucleus GO:0005634 10.06 AMOT CDKN1A CDKN1B CDKN2A CDKN2B FLG

Biological processes related to Papilloma according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.91 CDKN1A CDKN1B CDKN2A CDKN2B PTEN RB1
2 negative regulation of cell growth GO:0030308 9.85 CDKN1A CDKN1B CDKN2A TP53
3 G1/S transition of mitotic cell cycle GO:0000082 9.83 CDKN1A CDKN1B CDKN2A RB1
4 Ras protein signal transduction GO:0007265 9.8 CDKN1A CDKN2A RB1 TP53
5 keratinocyte differentiation GO:0030216 9.79 FLG IVL KRT10
6 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.78 CDKN1A CDKN1B TP53
7 negative regulation of epithelial cell proliferation GO:0050680 9.78 CDKN1B CDKN2B PTEN RB1
8 peptide cross-linking GO:0018149 9.77 FLG IVL KRT10
9 protein kinase B signaling GO:0043491 9.74 CDKN1A CDKN1B PTEN
10 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.73 CDKN1A CDKN2B PTEN RB1
11 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.71 CDKN1A CDKN1B PTEN
12 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.69 CDKN1A CDKN1B CDKN2A
13 mitotic cell cycle arrest GO:0071850 9.63 CDKN1A CDKN1B
14 response to arsenic-containing substance GO:0046685 9.63 CDKN1A PTEN
15 replicative senescence GO:0090399 9.63 CDKN1A CDKN2A TP53
16 cell cycle arrest GO:0007050 9.63 CDKN1A CDKN1B CDKN2A CDKN2B RB1 TP53
17 hemidesmosome assembly GO:0031581 9.62 KRT14 KRT5
18 hepatocyte apoptotic process GO:0097284 9.62 KRT8 RB1
19 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.62 CDKN1A CDKN1B CDKN2B PTEN
20 prostate gland growth GO:0060736 9.6 PTEN UBE3A
21 signal transduction by p53 class mediator GO:0072331 9.58 CDKN1A TP53
22 negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 9.58 CDKN2A CDKN2B PTEN
23 negative regulation of cyclin-dependent protein kinase activity GO:1904030 9.56 CDKN1A CDKN1B
24 negative regulation of phosphorylation GO:0042326 9.56 CDKN1A CDKN1B CDKN2A CDKN2B
25 keratinization GO:0031424 9.5 IVL KRT10 KRT13 KRT14 KRT20 KRT5
26 cornification GO:0070268 9.23 FLG IVL KRT10 KRT13 KRT14 KRT20
27 cell cycle GO:0007049 10.06 CDKN1A CDKN1B CDKN2A CDKN2B RB1 TP53

Molecular functions related to Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.63 CDKN1A CDKN1B CDKN2A CDKN2B PTEN TP53
2 disordered domain specific binding GO:0097718 9.43 CDKN2A RB1 TP53
3 structural molecule activity GO:0005198 9.35 FLG IVL KRT10 KRT13 KRT8
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.92 CDKN1A CDKN1B CDKN2A CDKN2B
5 protein binding GO:0005515 10.28 AMOT CDKN1A CDKN1B CDKN2A CDKN2B FLG

Sources for Papilloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....